Gorilla Tech Grの空売り状況は、投資家がGorilla Tech Grの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Gorilla Tech Gr (NASDAQ:GRRR) 株価情報, 空売り情報

Gorilla Tech Gr

Gorilla Technology Gr

Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.

Gorilla Technology Group Inc. - Ordinary shares

Gorilla Technology Group Inc

<a href="https://www.wsj.com/tech/elon-musk-trump-openai-stargate-abu-dhabi-e2689615" title="https://www.wsj.com/tech/elon-musk-trump-openai-stargate-abu-dhabi-e2689615">https://www.wsj.com/tech/elon-musk-trump-openai-stargate-abu-dhabi-e2689615</a>

News

Global

MSFT

'Elon Musk Tried To Block Sam Altman's Big Ai Deal In The Middle East; Musk Warned That Trump Wouldn't Bless OpenAI Data-Center Project Unless His xAI Company Was Added' - WSJ

Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) is pulling the plug on its ACURATE neo2 and <a href="https://www.benzinga.com/general/health-care">Prime aortic valve systems</a>.
What Happened: The medical technology giant halted global sales and abandoned regulatory pursuits—including a long-sought FDA approval—after escalating demands from health authorities rendered the effort too costly. 
Despite the setback, the Marlborough, Massachusetts-based company signaled confidence in its broader portfolio, affirming that it remains on track to hit its financial targets for the quarter and full year.
Also, Boston Scientific is no longer pursuing U.S. Food And Drug Administration (FDA) approval for ACURATE.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry</a>
The company based its decision on recent discussions with regulators. There have been increased clinical and regulatory requirements to maintain regulatory approvals in global markets.
The additional resources and investments needed to satisfy these requirements are prohibitive for the company.
Boston Scientific, in an SEC <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000885725/000088572525000033/bsx-20250528.htm">filing</a>, stated that it expects to achieve organic sales guidance for the second quarter and 2025.
<ul class="wp-block-list">
<li>Outlook: Boston Scientific forecasts net sales growth of approximately 15%-17% in 2025 on a reported basis and around 12%-14% on an organic basis, compared to prior guidance of 12.5%-14.5% and <a href="https://www.benzinga.com/general/health-care/25/04/44952308/boston-scientific-raises-annual-outlook-after-strong-heart-devices-sales-in-q1-announces-cfo-transition" target="_blank" rel="noreferrer noopener">10%-12%, respectively</a>.</li>
<li>The company estimates 2025 adjusted EPS of $2.87-$2.94 compared to prior guidance of $2.80-$2.87 and the consensus of $2.86.</li>
<li>The company estimates second quarter 2025 net sales growth of approximately 17.5%-19.5% on a reported basis and approximately 13%-15% on an organic basis, with adjusted EPS of 71-73 cents compared to consensus of 71 cents.</li>
</ul>
The company is not reaffirming its second quarter and full year 2025 GAAP EPS guidance and expects to provide more information during its second quarter 2025 earnings call.
<ul class="wp-block-list">
<li>Boston Scientific estimated 2025 GAAP earnings of $1.86-$1.93 per share and second-quarter earnings of $0.45&nbsp;to&nbsp;$0.47 per share.</li>
</ul>
Price Action: Boston Scientific stock is down 0.98% at $105.13 at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45643848/macys-feels-tariffs-and-consumer-spending-heat-cuts-profit-forecast" target="_blank" rel="noreferrer noopener">Macy&#8217;s Feels Tariffs And Consumer Spending Heat, Cuts Profit Forecast</a></li>
</ul>
Image: Shutterstock

Earnings

Large Cap

Health Care

Movers

Trading Ideas

General

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook

<a href="https://www.ft.com/content/2c0db765-03ac-4820-8a02-806469848bee">https://www.ft.com/content/2c0db765-03ac-4820-8a02-806469848bee</a>

CDNS

SNPS

'Trump Orders US Chip Designers To Stop Selling To China; US Commerce Dept Told Electronic Design Automation Groups, Including Cadence, Synopsys, Siemens EDA, To Stop Supplying Their Technology To China' - Financial Times

WIIM

Shares of Synopsis and Cadence Design Systems are trading lower following a report indicating President Trump ordered chip designers to stop selling to China.

Cryptocurrency markets were down on Wednesday despite Vice President JD Vance&#8217;s vow of support for the digital asset industry at the Bitcoin <a href="https://www.benzinga.com/topic/bitcoin">Conference in Las Vegas.</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$107,671</td>
<td>-1.9%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,647</td>
<td>-1.3%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$170.62</td>
<td>-4.6%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.25</td>
<td>-3.7%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2192</td>
<td>-3.7%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.0000141</td>
<td>-2.9%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows large transaction volume increasing by 12% and daily active addresses down by 8%.</li>
<li>Coinglass data reports 81,179 traders were liquidated in the past 24 hours for $203 million.</li>
</ul>
Notable Developments:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45653063/coin-of-the-day-sui-wobbles-after-exploit-can-it-rebound">Coin Of The Day: SUI Wobbles After Exploit—Can It Rebound?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45654053/blackrock-to-take-10-stake-in-circles-ipo">BlackRock To Take 10% Stake In Circle&#8217;s IPO</a></li>
<li><a href="https://www.benzinga.com/25/05/45645265/dogecoin-slips-to-0-22-as-liquidations-spike-200-crucial-support-at-0-21">Dogecoin Slips To $0.22 As Liquidations Spike 200%, Crucial Support at $0.21</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45652549/vice-president-jd-vance-predicts-100m-bitcoin-holders-the-us-ought-to-be-leaning-into-bitcoin">Vice President JD Vance Predicts 100M Bitcoin Holders: &#8216;The US Ought To Be Leaning Into Bitcoin</a></li>
</ul>
Trader Notes: Prominent analyst Ali Martinez <a href="https://x.com/ali_charts/status/1927756641987871184">pointed out</a> that $106,800 is a crucial support zone for Bitcoin that needs to hold to prevent a steeper drop.
Trader Altcoin Sherpa <a href="https://x.com/AltcoinSherpa/status/1927781129261666714">said</a> he is not rushing into positions and doesn&#8217;t know where the market will go in the short term, advocating for a &#8220;move slow&#8221; approach in tough conditions.
Trader Altcoin Psycho <a href="https://x.com/AltcoinPsycho/status/1927754530906632306">sees</a> a &#8220;big moment&#8221; coming up for Solana, with $140 to $150 as a &#8220;great zone&#8221; for bids in case price declines to that level.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">big moment coming up for solana as it approaches the mid-point of this 6 month range. this type of price compression under resistance has resolved well for bulls lately. but in case it doesn&#39;t, $140-$150 is a great zone for spot bids imo <a href="https://t.co/mI7xK2EYOl">pic.twitter.com/mI7xK2EYOl</a>
&mdash; Psycho (@AltcoinPsycho) <a href="https://twitter.com/AltcoinPsycho/status/1927754530906632306?ref_src=twsrc%5Etfw">May 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45646680/trump-familys-expanding-crypto-ties-raise-questions-on-ethics-influence-and-investor-risk">Trump Family&#8217;s Expanding Crypto Ties Raise Questions On Ethics, Influence, And Investor Risk</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Slide As VP Vance Pledges Crypto Support

Rocket Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) on Tuesday announced an update related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">and intellectual disability</a>.
A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The patient passed away after an <a target="_blank" href="https://www.benzinga.com/25/05/45621333/rocket-pharma-reports-patient-death-in-rare-disease-gene-therapy-trial-fda-puts-clinical-hold" rel="noreferrer noopener">acute systemic infection</a>.
Needham analyst Gil Blum downgraded Rocket Pharmaceuticals from Buy to Hold, with a Nil price forecast from $42 earlier. The analyst cited increased uncertainty around the company&#8217;s main value driver as the key reason for the downgrade.
Also Read: <a href="https://www.benzinga.com/government/regulations/25/05/45340465/bill-ackman-slams-subsidies-for-contributing-to-37-trillion-national-debt-hails-trumps-drug-price-order">Bill Ackman Slams Subsidies For Contributing To $37 Trillion National Debt, Hails Trump&#8217;s Drug Price Order</a>
&#8220;We continue to have a favorable view of RP-A501&#8217;s efficacy; however, we see increased uncertainty for the product given safety concerns,&#8221; Blum said in an analyst note.
Blum anticipates limited readthrough to Rocket&#8217;s other AAV programs, which utilize simpler immunosuppression regimens.
Chardan Research analyst Geulah Livshits also lowered its price target from $46 to $17 while <a href="https://www.benzinga.com/quote/RCKT/analyst-ratings" target="_blank" rel="noreferrer noopener">maintaining the Buy rating</a>.
While the disclosure does not negate the benefit reported for the program, the patient death and commentary regarding instances of TMA impact the benefit/risk profile of RP-A501, Livshits said in an analyst note.
Livshits reduced the probability of success from 70% to 40%, given CBER leadership&#8217;s focus on benefit/risk, pending more details regarding agency feedback and next steps.
The analyst projects a slower uptake among the Danon population (3.6% by 2030E), assuming greater caution among prescribers.
Chardan notes the company hasn&#8217;t revealed how many patients have been treated in the trial so far but said the study is currently over-enrolled, with more patients ready to begin treatment.
Management mentioned several possible next steps, such as switching to a simpler immunomodulatory treatment, using existing complement inhibitors known to be safe, and continuing to exclude patients who are genetically predisposed to complement activation.
Chardan highlights that it&#8217;s still unclear whether other immunomodulatory treatments could reduce the risk of TMA. There&#8217;s no timeline for when the company might align with the FDA and restart the trial. Additional changes like enrolling more patients may be required, which could cause further delays.
Given this uncertainty, the topline results are expected to come later than the previously guided mid-2026 timeframe.
Other analyst reactions:
<ul class="wp-block-list">
<li>Jefferies downgraded Rocket Pharmaceuticals from Buy to Hold and lowered the price target from $29 to $2.5.</li>
<li>Leerink Partners downgraded Rocket Pharmaceuticals from Outperform to Market Perform, lowering the price target from $37 to $8.</li>
<li>Scotiabank maintains Rocket Pharmaceuticals with a Sector Outperform, lowering the price target from $51 to $19.</li>
</ul>
Price Action: RCKT stock is trading higher by 6.44% to $2.48 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45655477/analyst-bullish-on-ultragenyx-poised-for-growth-with-six-drug-approvals-expected-by-2028">Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028</a></li>
</ul>
Image via Shutterstock

Analyst Color

Biotech

Downgrades

Price Target

Analyst Ratings

RCKT

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) is in the news with its <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45617449/salesforce-strikes-8-billion-acquisition-to-boost-ai-and-data-cloud-power">$8 billion buyout </a>of data management company Informatica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFA#NYSE">INFA</a>), an ambitious foray into the AI and data integration business. But the tech behemoth isn&#8217;t only in the spotlight for the deal –investors are also eagerly <a href="https://www.benzinga.com/trading-ideas/technicals/25/05/45646698/salesforce-inc-ai-ambitions-vs-stock-realities-ahead-of-q1-earnings-reveal">awaiting its fiscal Q1 2026 earnings release</a>, due after the market close Wednesday. Between a fresh M&amp;A appetite and expanding AI roots, CRM-focused funds could be on the cusp of a data-driven rally.
ETFs In The Spotlight
The Informatica acquisition and the expected earnings release have implications for a number of <a href="https://www.benzinga.com/etfs">ETFs that have big stakes in Salesforce</a>:
iShares Expanded Tech-Software Sector ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IGV#BATS">IGV</a>): 7.4% weightage
First Trust Dow Jones Internet Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDN#NYSE">FDN</a>): 5.4% weightage
FT Vest Dow Jones Internet &amp; Target Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FDND#BATS">FDND</a>): 5.4% weightage
These ETFs would stand to benefit if Salesforce&#8217;s quarterly earnings beat or meet forecasts and if the market perceives the Informatica acquisition as a strategic play in the growing AI space.
Can Salesforce Deliver?
Analysts are calling for Salesforce to post adjusted earnings per share (EPS) of $2.55 on revenue of $9.75 billion, improving year over year from $2.44 EPS and $9.13 billion in revenue. Such a performance would demonstrate the company&#8217;s ongoing growth trend, but at a more tempered rate than what it experienced during its previous years of explosive expansion.
The earnings announcement is especially important since it will give us clues on how Salesforce&#8217;s recent strategic actions, such as acquiring Informatica, will affect its financial well-being and competitive standing in the AI-powered enterprise software industry.
Bottom Line
The dual emphasis by Salesforce on strategic acquisitions as well as strong earnings performance make it an important contributor to the AI and enterprise software industries. Both investors and ETF observers will be listening to the Q1 earnings announcement for signals about the direction of the company and the wider ramifications for tech-themed investment vehicles.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45649748/abercrombie-is-hot-again-heres-why-your-retail-etf-didnt-get-the-memo">Abercrombie Is Hot Again — Here&#8217;s Why Your Retail ETF Didn&#8217;t Get The Memo</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

ETFs

First Trust Dow Jones Internet Index Fund

First Trust Exchange-Traded Fund IV FT Vest Dow Jones Internet & Target Income ETF

FDND

INFA

CRM-Powered ETFs In Focus As Salesforce Bets Big On AI With $8B Informatica Deal Ahead Of Q1 Results

BofA Securities analyst Peter T. Galbo initiated coverage on Primo Brands Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRMB#NYSE">PRMB</a>),<a target="_blank" href="https://www.benzinga.com/quote/PRMB/analyst-ratings" rel="noreferrer noopener"> with a price forecast of $42.</a>
Galbo notes that Primo Brands stock is expected to appreciate over the next 12 months as the company realizes cost synergies, targeting $300 million in EBITDA by 2026.
If valuation multiples stay steady, this should support growth in enterprise and equity value.
Also Read:<a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45582935/ftc-scraps-pepsico-price-discrimination-case-in-3-0-vote-marking-major-shift-as-trump-era-leadership-reverses-biden-crackdown" rel="noreferrer noopener"> FTC Scraps PepsiCo Price Discrimination Case In 3-0 Vote, Marking Major Shift As Trump-Era Leadership Reverses Biden Crackdown</a>
Additional positives include bottled water&#8217;s rising share in U.S. liquid refreshment beverages and reduced focus on the category by other CSD producers, which could improve overall profitability.
The North American-based bottled and packaged water producer, which has 30 brands, including Poland Spring and Pure Life, was formed from the November 2024 merger of Primo Water and Blue Triton.
Galbo recalls that Primo Brands initially projected ~$200 million in cost synergies by 2026 at the time of its merger, later raising the target to ~$300 million (22% of FY24 combined adjusted EBITDA) during its February 2025 investor day.
While such projections are often met with skepticism, in Primo&#8217;s case, the company has clear overlapping costs to cut across brands, headcount, factories, fleets, and depots over the next seven quarters.
Favorably, by the end of 1Q25, Primo was already achieving ~$20 million in quarterly synergies, with limited reliance on harder-to-achieve revenue synergies.
The analyst observes that U.S. bottled water has outpaced total liquid refreshment beverages. This has boosted bottled water&#8217;s volume share to 38.4%, up from 36.7% in 2019 and 30.7% in 2014.
The trend is expected to persist as U.S. consumers increasingly favor healthier options over carbonated soft drinks.
Galbo sees additional support for Primo Brands&#8217; 3%-5% annual net sales growth target in its ongoing expansion of premium offerings, including Saratoga and Mountain Valley.
For FY25, the analyst&#8217;s adjusted EBITDA forecast of $1.610 billion includes $200 million of synergies, implying the remaining $63 million of incremental YoY EBITDA is driven almost entirely by sales growth as opposed to underlying operational improvement.
Likewise, the FY26 EBITDA assumes no underlying operational improvement, with the analyst&#8217;s $1.756 billion estimate driven mainly by $100 million of synergies.
Price Action: PRMB shares are trading higher by 2.95% to $33.17 at last check Wednesday.
Read Also:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45581845/judge-blocks-trumps-mass-federal-layoffs-citing-need-for-congressional-approval" target="_blank" rel="noreferrer noopener">Judge Blocks Trump's Mass Federal Layoffs, Citing Need For Congressional Approval</a></li>
</ul>
Photo: Shutterstock

Equities

Markets

PRMB

Primo Brands Coverage Initiated: Analyst Sees EBITDA Gains From Cost Cuts, Bottled Water Momentum

One middle-class budgeter had a cold brew of a wake-up call when they opened their finance app and realized their <a href="https://www.benzinga.com/news/earnings/25/04/45084597/starbucks-misses-q2-earnings-estimates-ceo-says-optimism-has-turned-into-confidence-i-see-more-opportunity-than-i-imagined">Starbucks habit </a>had quietly snowballed into a four-digit expense.
"Just realized I spent $1,089 at Starbucks over the past 7 months. What the actual hell am I doing??" <a href="https://www.reddit.com/r/MiddleClassFinance/s/jRzrmhV0Cx">the Reddit user wrote</a>, bewildered. "Somehow I went from $45 in January to $334 in April?? And then still dropped $237 in May even after trying to ‘cut back.' I basically have a coffee mortgage at this point."
Yes, a coffee mortgage. And they're not alone.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
From drive-thru cold foams to double matcha oatmilk lattes, Americans love their Starbucks — maybe a little too much. In fact, nearly 50% of U.S. consumers picked Starbucks as their go-to brand, according to a <a href="https://www.statista.com/statistics/1327923/favorite-coffee-brands-among-us-consumers/">2023 Statista survey</a>. That's not just a caffeine preference — that's loyalty with whipped cream on top.
The Redditor even attached a chart for "curious caffeine addicts," showing just how fast those $4 pick-me-ups morphed into twice-a-day $7 matchas. And the comments? A mix of confessions, judgment, and unsolicited frugal advice.
"No lie, it feels good when they don't even have to ask your name for the order anymore," one user said. "Signed, someone who isn't brave enough to see what they used to spend a year at Starbucks."
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a>
Another was more blunt: "Have you considered learning to make the coffee you like at home? Even if your Starbucks drink of choice is one of their fancy lattes, you've spent more in the last 7 months than it costs to buy a really nice espresso machine."
That's a fair point — especially considering what some finance pros have to say. <a href="https://www.benzinga.com/personal-finance/24/07/39693693/suze-orman-tells-oprah-instead-of-starbucks-everyday-a-25-year-old-putting-100-a-month-into-roth">Suze Orman famously warned</a> that your daily coffee habit could be tanking your financial future, once saying, "You are peeing $1 million down the drain" by buying coffee out instead of investing the money. Kevin O'Leary — Mr. Wonderful himself — <a href="https://www.benzinga.com/personal-finance/25/02/43946260/kevin-oleary-says-people-waste-15k-a-year-on-stupid-stuff-like-buying-lunch-at-work-it-costs-you-99-cents-to-make-a-sandwich">called it "stupid" spending</a> and swore he's never bought a cup of coffee in his life unless it came from his own kitchen.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
To put it in perspective: $1,089 is roughly what some Americans pay in rent or utilities. That's a weekend getaway. A starter investment portfolio. Or yes, a top-tier espresso machine with enough money left over for fancy syrups and a milk frother.
So while no one's saying to ditch your favorite green straw forever, it might be worth asking: Are you sipping joy — or just swiping into autopilot?
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

'Just Realized I Spent $1,089 at Starbucks in 7 Months' — A Middle-Class Coffee Addict Wonders If Blowing a Mortgage Payment on Lattes Is Normal

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) stock has soared nearly 500% over the past year driven by its positioning in the AI space. One analyst believes the stock has a lot more runway ahead with the AI revolution still <a href="https://www.benzinga.com/government/regulations/25/05/45403100/bullish-for-nvidia-tesla-palantir-microsoft-alphabet-amazon-ai-revolution-is-coming-to-the-saudi-kingdom-says-wedbushs-dan-ives">in its early stages</a>.
What To Know: Wedbush&#8217;s Dan Ives famously calls Palantir the &#8220;Messi of AI&#8221; because he expects the company to be one of the biggest beneficiaries of the AI boom. He&#8217;s been right so far, and he&#8217;s not pulling back on his bullish stance in the slightest.
Wednesday on CNBC&#8217;s &#8220;Squawk On The Street,&#8221; Ives predicted that Palantir stock will more than triple in the coming years and trade above $400 per share.
&#8220;That&#8217;s why it&#8217;s the &#8216;Messi of AI.&#8217; I believe we&#8217;re talking about a trillion-dollar market cap for Palantir in the next few years, and I think when you look at what [Alex] Karp and Palantir are doing, they, along with Nvidia, will be leading the AI revolution,&#8221; Ives said.
The other massive beneficiary of AI has been NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which is scheduled to report earnings after the market close on Wednesday. Ives expects the results to act as a &#8220;bright green light&#8221; for tech investors as demand continues to easily outweigh supply. 
There&#8217;s only one chip in the world fueling the AI revolution and that&#8217;s Nvidia&#8217;s, Ives said, adding that AI is driving the fourth Industrial Revolution. He expects Nvidia&#8217;s quarterly report to be the catalyst that kicks off a run to new highs for tech.
Check This Out: <a href="https://www.benzinga.com/25/05/45644145/nvidia-stock-is-bullish-ahead-of-q1-earnings-but-will-h20-chip-woes-dampen-the-party">Nvidia Bullish Ahead Of Q1 Earnings, But Will H20 Chip Woes Dampen The Party?</a>
Many analysts disagree with Ives on Nvidia and Palantir, especially Palantir, given its massive surge over the past year and its becoming one of the best-performing names in the S&amp;P 500.
Ives told CNBC that many analysts hated Palantir when it hit $25, despised it when it hit $50 and $100, but the deals keep coming in and the company is doing it without a traditional sales team. 
&#8220;I believe it&#8217;s a trillion dollar market cap in the next two to three years, and I think look, haters hate on this one, but I think they continue to underestimate the pure success that they&#8217;re seeing,&#8221; Ives said. 
&#8220;Karp, he&#8217;s playing chess, others are playing checkers. And I think you are starting to realize more and more in government, enterprise, and that&#8217;s why you cannot talk AI revolution without saying Palantir.&#8221;
In order for Palantir to reach a $1 trillion market cap valuation, the stock would need to climb to $427.35 per share. Palantir had a market cap of $291.19 billion as of Tuesday&#8217;s close. 
PLTR Price Action: <a href="http://benzinga.com/quote/PLTR">Palantir shares</a> were up 1.15% at $124.81 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45636050/palantir-partners-with-bain-company-to-accelerate-global-enterprise-ai-adoption">Palantir Partners With Bain &amp; Company To Accelerate Global Enterprise AI Adoption</a></li>
</ul>
Photo: slyellow/Shutterstock.

Long Ideas

NVDA

PLTR

Tech Analyst Expects Palantir Stock To Rise Above $400 As AI Revolution  Kicks Into Gear

On Wednesday, William Blair initiated coverage on Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-<a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">rare genetic diseases</a>.
Since 2017, the company has commercialized four products, which generated $560 million in revenue in 2024, up 29% year-over-year. In the first quarter of 2025, sales increased <a href="https://www.benzinga.com/pressreleases/25/05/g45234765/ultragenyx-reports-first-quarter-2025-financial-results-and-corporate-update" target="_blank" rel="noreferrer noopener">28% to $139.29 million</a>.
Ultragenyx expects fiscal 2025 sales of $640 million-$670 million versus <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $655.02 million</a>.
&#8220;We anticipate Ultragenyx&#8217;s legacy products will continue to provide a strong revenue foundation for the company through the early 2030s,&#8221; writes William Blair analyst Sami Corwin.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44523017/ultragenyx-is-uniquely-positioned-in-long-term-remains-on-jpmorgans-focus-list" rel="noreferrer noopener">Ultragenyx Stays On JPMorgan&#8217;s Focus List As Analyst Highlights Strong Long-Term Positioning</a>
William Blair initiated coverage <a href="https://www.benzinga.com/quote/RARE/analyst-ratings">with an Outperform rating</a>, writing that the company is at an inflection point. Potentially, six additional therapeutics will be approved by the end of 2028, including three approvals in the next 18 months.
Corwin notes that these additional assets synergize with Ultragenyx&#8217;s existing commercial portfolio, aiding in strong commercial launches. She projects the company&#8217;s expanding revenue stream, supplemented by the potential receipt of three priority review vouchers, could enable the company to achieve GAAP profitability in 2027 and beyond.
William Blair noted that regulatory decisions and clinical data could be catalysts for the stock in the near term. Specifically, positive results from the Phase 3 trial of setrusumab in osteogenesis imperfecta (OI) could lead to significant upside.
Corwin projects the products could begin contributing to the top line as early as the fourth quarter of 2025 and could lead to a major revenue inflection in 2026 with the potential approval of pertuzumab in OI.
William Blair views setrusumab as a blockbuster product and estimates peak revenue of $2.4 billion in 2037, $1.4 billion of which will go to Ultragenyx.
Price Action: RARE stock is down 1.65% at $34.50 at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45629309/why-is-rare-lung-disease-focused-savara-stock-trading-lower-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?</a></li>
</ul>
Photo: Shutterstock

Initiation

RARE

Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028

Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) shares are trading higher on Wednesday after the company announced the appointment of a new CEO on Tuesday, and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/sports/25/05/45632213/vail-resorts-stock-climbs-after-company-announces-ceo-transition" rel="noreferrer noopener">reaffirmed 2025 guidance.</a>
Vail Resorts announced that&nbsp;Rob Katz, executive chair and former CEO, has been appointed current CEO. Katz will succeed&nbsp;Kirsten Lynch, who has stepped down as CEO and as a director of the board.
Here are the key analyst takes on the development:
<ul class="wp-block-list">
<li>JP Morgan analyst Matthew R. Boss upgraded the stock from Underweight to Neutral, with a price forecast of $167.</li>
<li>BofA Securities analyst Shaun C. Kelley reiterated the Neutral rating on the stock, raising the price forecast from $160 to $175.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/05/45645056/gold-etf-bleeds-money-at-fastest-pace-in-3-years-is-the-safe-haven-trade-over" rel="noreferrer noopener">Gold ETF Bleeds Money At Fastest Pace In 3 Years — Is The Safe-Haven Trade Over?</a>
<h2 class="wp-block-heading">JP Morgan</h2>
JP Morgan analyst Boss stated in the analyst note that with Vail Resorts nearing the end of industry normalization challenges by FY25 and former CEO Katz returning to lead, the company may be approaching an inflection point in both revenue and earnings.
This outlook is backed by unique growth drivers, Vail Resorts's portfolio of top-tier resorts—including the five most visited in North America—and its advance commitment strategy through various Epic Pass options, which helps reduce seasonal risk.
Boss sees a unique chance for the firm to accelerate its model under returning CEO Katz, who previously led Vail Resorts from 2006 to 2021 and now resumes his leadership role.
With a history of driving double-digit EBITDA growth over 15+ years and a focus on meaningful, quality-driven expansion, Katz may help the company recapture around 250bps of EBITDA margin versus FY19 through stronger operating leverage.
<h2 class="wp-block-heading">BofA Securities</h2>
Bank of America analyst Kelley writes that Katz's return signals urgency, highlighted by a 10% after-hours stock jump and expectations of renewed revenue momentum.
While major shifts to Vail's commitment strategy, efficiency plans, or dividend approach seem unlikely for now, Katz, who previously led transformative initiatives like the Epic Pass and M&amp;A, could drive reinvention, given his role in shaping the industry's current model.
Price Action: MTN shares are trading higher by 12% to $169.66 at last check Wednesday.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45655193/applovins-valuation-reflects-high-expectations-for-monetization-expansion-analyst" target="_blank" rel="noreferrer noopener">AppLovin&#8217;s Valuation Reflects High Expectations For Monetization Expansion: Analyst</a></li>
</ul>
Photo by Simone Hogan via Shutterstock

Upgrades

Vail Resorts CEO Shake-Up Spurs Hopes Of Growth Rebound

JPMorgan analyst Sebastiano Petti maintained an Overweight rating on United States Cellular (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) and lowered the<a href="https://www.benzinga.com/quote/usm/analyst-ratings" target="_blank" rel="noreferrer noopener"> price forecast from $88 to $85</a>.
The analyst says that he foresees additional opportunities to unlock value and anticipates substantial capital returns for shareholders within the next year.
The analyst notes the commencement of T-Mobile&#8216;s exchange offer for up to $2.044 billion of US Cellular debt, which he believes indicates the deal&#8217;s imminent close in the coming weeks, as such offers typically <a target="_blank" href="https://www.benzinga.com//node/43883619" rel="noreferrer noopener">precede closing within 40 days</a>.
Consequently, Petti now expects T-Mobile&#8217;s acquisition of US Cellular&#8217;s wireless operations to finalize on July 1, aligning with expectations for a mid-2025 close.
The analyst now estimates that the company could distribute up to $28-$30 per share in special dividends by mid-2026.
This comprises of an estimated $9-$11 per share from the T-Mobile deal, an additional $10 per share following the sale of spectrum to AT&amp;T, and $9 per share from the Verizon spectrum deal, says the analyst.
The analyst notes that USM continues its focus on cost optimization, but increased industry-wide competition is expected to impact its 2025 financials.
Petti raised the 2025 service revenue estimate to $2.95 billion (up 0.3%) due to higher postpaid ARPU, which is projected to grow 1.2% year-over-year to $52.44, despite anticipated lower volumes in postpaid, handset, and prepaid segments.
Conversely, the analyst lowered 2025 EBITDA estimate by 3% to $970 million, resulting in margins of 26.4% (down from 26.9%).
Although first-quarter capital spending was significantly below the expectations ($53 million versus $133 million prior), the analyst is only marginally trimming 2025 capital expenditure by 2% to $520 million.
Price Action: USM shares are down 0.76% at $62.80 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45465922" target="_blank" rel="noreferrer noopener">Charter Seals&nbsp;$34.5 Billion&nbsp;Cox Merger Deal, Creating Powerhouse To Battle Streaming, Wireless Rivals</a></li>
</ul>
Photo: Shutterstock

US Cellular Deal Could Unlock Major Payouts: JPMorgan Expects T-Mobile Acquisition To Finalize By July

Stock Split

VXRT

Vaxart Board Commits To High End Of 1-for-20 Reverse Stock Split Ratio

Needham analyst Bernie McTernan <a target="_blank" href="https://www.benzinga.com/quote/APP/analyst-ratings" rel="noreferrer noopener">reiterated its Hold rating</a> on AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) on Wednesday.
AppLovin&#8217;s primary tool for future growth is <a target="_blank" href="https://www.benzinga.com/insights/analyst-ratings/25/05/45642953/where-applovin-stands-with-analysts" rel="noreferrer noopener">Axon 2</a>, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
In McTernan&#8217;s third AppLovin Ecommerce Tracker, the total number of websites in his sample using Axon grew by +3% compared to last month to 323, which includes 18 gross adds and 7 churns.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45323056/applovins-rapid-ad-growth-ai-gains-drive-hike-in-analyst-price-forecast" rel="noreferrer noopener">AppLovin&#8217;s Rapid Ad Growth, AI Gains Drive Hike In Analyst Price Forecast</a>
The seven churned websites were more than the one churn last month, the analyst noted. However, two of the seven companies shut down their businesses, he said in the analyst note.
McTernan said Apparel, Footwear &amp; Accessories was the largest category gainer in the past month, with 10 gross adds and one churn.
The analyst noted that AppLovin announced in December that the company had 600 e-commerce brands and a $1 billion ad spend run rate.
Given the relatively modest growth and essentially unchanged pixel helper count, he does not believe self-service has launched yet.
McTernan noted one big brand add the Pixel this month, Reebok, which Authentic Brands Group, a private brand management company, owns. Press reports indicate Reebok does ~$5 billion in sales, which is in the bottom quartile for revenue among the 70 big brands he sampled. Authentic Brands Group combined for $32 billion+ of revenue, the analyst said. Some of the brands that added the Pixel include Champion, Juicy Couture, and Vince Camuto, he said.
Other brands ABG owns but not using the Pixel include Nautica, Aeropostale, Lucky, Brooks Brothers, Sperry, Spyder, Ted Baker, Forever 21, Hunter, McTernan noted.
As a reminder, the analyst noted that focusing on some of the larger brands in his dataset is essential as they have the most remarkable ability to scale advertising spending on the platform. He considered ~70 websites in his tracker big brands.
McTernan noted no change to AppLovin&#8217;s reported user count for the Axon pixel at 2k. The analyst noted that the user count crossed from 1k to 2k between February 28 and March 5, which he noted means the user count passed 1,500 that week.
AppLovin projected second-quarter revenue of $1.21 billion and EPS of $1.86.
Weighing in on AppLovin&#8217;s valuation, McTernan stated that the company&#8217;s valuation has become one of the most expensive within their coverage group. This surge is driven by heightened expectations for the company&#8217;s ability to further monetize its advertising platform through new verticals, he noted.
Price Action:&nbsp;APP stock is trading higher by 1.29% to $385.83 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45380609" target="_blank" rel="noreferrer noopener">AppLovin Stock Surges On Strong Q1 Earnings And Tariff Truce Tailwinds</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Reiteration

Tech

AppLovin's Valuation Reflects High Expectations For Monetization Expansion: Analyst

BHVN

Biohaven Announces Plans To Initiate Pivotal Trials In Graves' Disease And In IgA Nephropathy In 2H 2025 And 1H 2026

On Friday, BOfA Securities analyst hosted Richard Aboulafia, a partner at AeroDynamic Advisory, to discuss expectations <a href="https://www.benzinga.com/analyst-ratings/analyst-color" target="_blank" rel="noreferrer noopener">for the upcoming 2025 Paris Air Show</a>.
The analyst says that regarding news of potential 50% EU tariffs, Aboulafia warned that the Air Show could foreshadow how future <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45585283/trump-tariff-threat-hits-europe-stocks-sink-as-50-duties-loom" target="_blank" rel="noreferrer noopener">international negotiations might unfold</a>.
The analyst notes that the EU might draw lessons from recent agreements in China and the Middle East, which mainly included aerospace and defense products.
Nevertheless, the analyst writes that given the EU&#8217;s own substantial aerospace and defense industry, which it aims to protect, U.S. aerospace and defense interests might become a point of contention rather than an incentive in these discussions.
Also Read: <a href="https://www.benzinga.com//node/45594990" target="_blank" rel="noreferrer noopener">DOJ Offers Boeing Deal To Avoid Criminal Charges Over 737 Max Crashes</a>
Regarding Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), Aboulafia views recent deals in the Middle East and China as setting a precedent for other nations&#8217; trade negotiations, suggesting orders will be held back as bargaining chips, noted the analyst.
The analyst writes that, for both Airbus SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/EADSY#OTC">EADSY</a>) and Boeing, Aboulafia doesn&#8217;t foresee many airlines placing large new orders, primarily due to a lack of new aircraft programs and existing backlogs exceeding 10 years for their most popular models.
Further, the analyst noted that, as previously disclosed, Aboulafia doesn&#8217;t anticipate any major new commercial aircraft program unveilings due to ongoing supply chain issues and global macroeconomic constraints.
In the defense sector, Aboulafia expects numerous companies to compete for subsystem roles on programs like NGAD/the F-47 and CCA.
Additionally, Aboulafia anticipates an outsized presence of unmanned aerial systems at the show, predicting a focus on lower-tech, expendable variants rather than highly sophisticated systems, says the analyst.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45583103" target="_blank" rel="noreferrer noopener">Trump&#8217;s Chosen Air Force One Contractor L3Harris To Pay $62 Million As Settlement For Misleading US Military</a></li>
</ul>
Photo: Shutterstock

European Aeronautic Defence And Space Unsponsored

EADSY

Will Paris Air Show Signal Shift In Aerospace Trade? Analyst Flags EU Tariff Risks, Order Delays

In a corporate cage match, two of the globe&#8217;s most dominant oil titans are fighting it out for a share of one of the world&#8217;s most coveted oil finds: Guyana. But while Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) are in the midst of arbitration, ETF investors may need to hold on tight. This courtroom battle could rock some of the <a href="https://www.benzinga.com/etfs">largest energy ETFs available</a>.
<h1 class="wp-block-heading">The Stakes: Oil, Ego — And An 11 Billion Barrel Bonanza</h1>
Behind the fight is Hess Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) 30% interest in a huge Guyanese oil project, which has roughly 11 billion barrels in projected reserves. Chevron said in 2023 it agreed to buy Hess for $53 billion, a transaction that would put it at the front of the Guyana boom. 
But Exxon, which already <a href="https://www.benzinga.com/markets/equities/24/06/39479711/exxon-mobil-rakes-in-billions-from-guyana-oil-deal-net-margin-tops-chip-giant-report">co-leads the Guyana project</a>, says it has pre-emptive rights to the stake. Arbitration gets underway in London this week, and sometime in late summer, a panel will <a href="https://www.benzinga.com/topic/oil">make a decision</a>.
<h1 class="wp-block-heading">ETF Fallout: Who&#8217;s Exposed To What?</h1>
The heavy hitters such as Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), iShares U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYE#NYSE">IYE</a>) and Vanguard Energy Index Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VDE#NYSE">VDE</a>) are carrying heavy loads of both Exxon and Chevron, between 35% and 40% combined weighting in each fund.
If either Exxon or Chevron prevails, one can anticipate a pop for these ETFs as the Guyana deal would mean long-term growth assets for the prevailing company.
Hess Corp. is smaller but essential in this saga. ETFs such as iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEO#BATS">IEO</a>) carry meaningful exposure to Hess, and therefore a front-row seat to either a lucrative M&amp;A payday or a disappointing fizz.
Additionally, merger arbitrage ETFs, such as NYLI Merger Arbitrage ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNA#NYSE">MNA</a>) and ProShares Merger ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MRGR#BATS">MRGR</a>), are likely to be betting on the Hess factor already. If the transaction gets delayed or blocked further, one can expect some readjustment.
<h1 class="wp-block-heading">Beyond the Big Oil Bets</h1>
As Chevron cuts jobs and balances new resources in Kazakhstan and the Gulf of Mexico, it also deals with <a href="https://www.benzinga.com/markets/25/02/44000386/trump-shuts-down-chevrons-venezuela-oil-permit-tightening-pressure-on-maduro-regime-crude-oil-prices-rise-on-supply-concerns">uncertainty in Venezuela</a>, where an operating license may be withdrawn. Exxon is increasing <a href="https://corporate.exxonmobil.com/locations/guyana/guyana-project-overview">production </a>in Guyana to 1.3 million barrels/day by 2027, greater than North Dakota&#8217;s Bakken Shale.
<h1 class="wp-block-heading">One Wrong Move = ETF Domino Effect</h1>
With activist investors watching Exxon and Chevron still under pressure to prove long-term growth, the arbitration&#8217;s outcome could drive major portfolio re-weightings, flows into specific funds or a rise in thematic oil and gas ETFs.
In short, this isn't just a battle over barrels, it's about which ETFs end up doing well and which might need a Band-Aid.
<h1 class="wp-block-heading">Final Thought</h1>
This Guyana brawl might be happening in a London arbitration chamber, but its aftershocks will be felt through world markets and ETF tickers. For investors, it&#8217;s time to look beyond the barrel and begin peering at the ticker tape.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45647794/why-kre-is-falling-behind-xlf-and-raising-flashbacks-of-the-svb-collapse-etf-market-senses-bank-trouble">KRE Falls Behind XLF, Sparks SVB Collapse Flashbacks: Are ETFs Sensing Bank Trouble?</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Commodities

Legal

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

iShares Dow Jones US Energy Sector Index Fund

MRGR

Exxon Stock Vs. Chevron: The 11 Billion Barrel Oil War That Could Shake Up Energy ETFs

MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) shares are trading higher Wednesday, continuing a sharp upward move fueled by retail momentum and recent announcements about the company's<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45622723/microcloud-hologram-stock-is-moving-higher-tuesday-whats-going-on"> progress in quantum technologies</a>.
What To Know: MicroCloud Hologram shares have gained over 80% during intraday trading Wednesday, with volume exceeding 43 million shares, well above its 100-day average of 1.1 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
The rally appears to be retail-driven as traders highlight the company's recent quantum initiatives. 
Last week, MicroCloud disclosed it had developed a new quantum supervised learning method, indicating it addresses key limitations in current quantum machine learning algorithms. The company also reported advances in quantum-enhanced imaging, specifically using holographic LiDAR based on time-frequency entanglement to achieve a 40dB signal-to-noise ratio. This technology advancement reportedly enables imaging of non-reflective targets in noisy environments.
The recent developments have gained traction on social media platforms as retail traders react to both the technical potential and the stock's low float. Only 4.73 million shares are available for public trading, and 13.52% of the float is currently sold short, which is likely contributing to increased volatility in the name. Institutional ownership remains minimal at just 0.32%, underscoring the retail-driven nature of the move.
Despite the current rally, MicroCloud shares remain down nearly 95% year-to-date. The stock hit a 52-week low of $5.37 last week before reversing course. The ongoing momentum highlights how small-cap, low-float stocks like MicroCloud can see sharp price increases in response to news flow combined with increasing retail interest.
HOLO Price Action: MicroCloud Hologram shares were up 82.8% at $11.04 at the time of publication Wednesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45651401/wall-street-stalls-as-treasury-yields-climb-again-ahead-of-nvidia-earnings-fed-minutes-whats-driving-markets-wednesday">Wall Street Stalls As Treasury Yields Climb Again Ahead Of Nvidia Earnings, Fed Minutes: What&#8217;s Driving Markets Wednesday? </a></li>
</ul>
Image: Shutterstock.

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

MicroCloud Hologram Stock Is Surging Again: What's Going On?

<ul>
<li>Optimized subcutaneous (SC) administration of BHV-1400 achieved rapid, deep, selective, and sustained lowering of Gd-IgA1, differentiating Biohaven's leading TRAP degrader for IgAN from the complement and BLyS/APRIL inhibitor competition.
<ul>
<li>Up to 81% reduction of Gd-IgA1 was observed, with reductions from baseline sustained for weeks after a single SC dose administration.</li>
<li>BHV-1400 brings precision immunology to the treatment landscape of IgAN as it was rationally designed to selectively remove galactose-deficient IgA1 (Gd-IgA1), the pathogenic antibody driver of the disease while sparing healthy antibodies IgA, IgG, IgE, and IgM.</li>
<li>Preservation of immunoglobulins, the complement system, and cell-mediated and humoral immunity offers key differentiation against immunosuppressive BLyS/APRIL inhibitors, complement inhibitors, and budesonide.</li>
<li>Based upon the rapid and deep reductions of Gd-IgA1 observed with subcutaneous BHV-1400, Biohaven plans to study BHV-1400 in patients with IgAN, initiating a pivotal trial in 2026 using urine protein-creatinine ratio (UPCR) as a surrogate endpoint for accelerated approval.</li>
</ul>
</li>
<li>Optimized SC administration of BHV-1300 has continued to demonstrate rapid, deep, and sustained lowering of total IgG in Phase 1 studies.
<ul>
<li>Recently generated clinical data shows that BHV-1300 achieved rapid, deep, and sustained lowering of total IgG, with reductions up to 87%.</li>
<li>Median maximum reductions of 83% were observed within 18 days of the first subcutaneous dose.</li>
<li>The range of IgG reductions possible with varying dosing paradigms of BHV-1300 allows for tunable dosing regimens tailored for acute and chronic disease management, with higher doses for acute disease management and lower, less frequent dosing for chronic disease management.</li>
<li>Based upon the rapid and deep reductions of IgG and favorable tolerability profile observed with BHV-1300, Biohaven plans to study BHV-1300 in patients with Graves' Disease and initiate pivotal trials in 2H 2025.</li>
</ul>
</li>
</ul>
NEW HAVEN, Conn., May 28, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today highlighted the success of its first MoDE&#x2122; and TRAP&#x2122; degraders in achieving key target pharmacodynamic endpoints and announced plans to initiate pivotal trials in Graves' Disease and in IgA nephropathy in 2H 2025 and 1H 2026, respectively at Biohaven's 2025 R&amp;D Day, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. The presentation slides from Biohaven's R&amp;D day for the TRAP and MoDE degraders and its other platforms will be available on the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4437235-1&amp;h=3793265758&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4177529-1%26h%3D1652257103%26u%3Dhttps%253A%252F%252Fir.biohaven.com%252Fevents-presentations%252Fevents%26a%3DEvents%2Band%2BPresentations%2Bpage&amp;a=Events+and+Presentations+page">Events and Presentations page</a> of the Biohaven website just prior to their presentations.
 &nbsp;

Biohaven Showcases MoDE And TRAP Degrader Innovations at R&D Day

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gorilla Technology Group, Inc. - GRRR

Gorilla Technology Files Lawsuit to Confront False Allegations and Protect Shareholders

Small Cap

GRRR Investors Have Opportunity to Join Gorilla Technology Group Inc. Fraud Investigation with the Schall Law Firm

Gorilla Technology Releases Full Year Audited Financials for 2024

Gorilla Technology Group Appoints Bruce Bower as Chief Financial Officer

Gorilla Technology Shares Repurchase and Insider Ownership Updates; To Announce Q1 Earnings

GRRR

Agora

Digital Turbine

Arqit Quantum

Bit Digital

CoreCard

Consensus Cloud Solutions, Inc. - Common Stock

Consensus Cloud Solns

Cerence

Digimarc

Domo

Viant Technology

Expensify

Helport AI

Kaltura

CS Disco

Mercurity Fintech Holding Inc. - American Ordinary Shares

Mercurity Fintech Holding

Mitek Systems

Materialise NV - American Depositary Shares

Materialise

OneConnect Financial Technology Co., Ltd. American Depositary Shares, each representing thirty ordinary shares

Comments

Gorilla Tech Gr

空売り

Gorilla Tech Gr (NASDAQ:GRRR) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル